Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, California 95817, United States.
ACS Synth Biol. 2024 Jun 21;13(6):1906-1915. doi: 10.1021/acssynbio.4c00181. Epub 2024 May 11.
Synthetic biology constitutes a scientific domain focused on intentional redesign of organisms to confer novel functionalities or create new products through strategic engineering of their genetic makeup. Leveraging the inherent capabilities of nature, one may address challenges across diverse sectors including medicine. Inspired by this concept, we have developed an innovative bioengineering platform, enabling high-yield and large-scale production of biological small interfering RNA (BioRNA/siRNA) agents via bacterial fermentation. Herein, we show that with the use of a new tRNA fused pre-miRNA carrier, we can produce various forms of BioRNA/siRNA agents within living host cells. We report a high-level overexpression of nine target BioRNA/siRNA molecules at 100% success rate, yielding 3-10 mg of BioRNA/siRNA per 0.25 L of bacterial culture with high purity (>98%) and low endotoxin (<5 EU/μg RNA). Furthermore, we demonstrate that three representative BioRNA/siRNAs against GFP, BCL2, and PD-L1 are biologically active and can specifically and efficiently silence their respective targets with the potential to effectively produce downstream antiproliferation effects by PD-L1-siRNA. With these promising results, we aim to advance the field of synthetic biology by offering a novel platform to bioengineer functional siRNA agents for research and drug development.
合成生物学是一个专注于通过对生物体的基因结构进行战略性工程设计,来赋予其新功能或创造新产品的科学领域。利用自然的固有能力,人们可以解决包括医学在内的各个领域的挑战。受这一概念的启发,我们开发了一种创新的生物工程平台,通过细菌发酵实现生物小分子干扰 RNA(BioRNA/siRNA)的高效、大规模生产。在此,我们展示了一种新的 tRNA 融合前体 miRNA 载体,它可以在活宿主细胞内产生各种形式的 BioRNA/siRNA 药物。我们报告了 9 种目标 BioRNA/siRNA 分子的高水平过表达,成功率达到 100%,每 0.25L 细菌培养物可产生 3-10mg 的 BioRNA/siRNA,纯度>98%,内毒素<5EU/μg RNA。此外,我们证明了三种针对 GFP、BCL2 和 PD-L1 的代表性 BioRNA/siRNA 是具有生物活性的,能够特异性和有效地沉默各自的靶标,并有可能通过 PD-L1-siRNA 产生有效的下游增殖抑制作用。有了这些有希望的结果,我们旨在通过提供一个新的平台来生物工程功能性 siRNA 药物,为研究和药物开发提供帮助,从而推动合成生物学领域的发展。